New drug shows promise for controlling Huntington's chorea
NCT ID NCT04400331
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 study tested the long-term safety of valbenazine in 154 people with Huntington disease who have chorea (uncontrolled movements). Participants either continued from a previous study or joined new. The goal was to see if valbenazine is safe and helps control chorea over time. Results may support its use as a long-term symptom management option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- valbenazine
- What this could lead to
- If successful, this could provide a long-term treatment option to reduce involuntary movements (chorea) in people with Huntington disease.
- What could go wrong
- This is an open-label study without a placebo group, so results may be less reliable. Side effects are possible, and the drug only manages symptoms, not the underlying disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOREA, HUNTINGTON are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Neurocrine Clinical Site
Birmingham, Alabama, 35294, United States
-
Neurocrine Clinical Site
Little Rock, Arkansas, 72205, United States
-
Neurocrine Clinical Site
La Jolla, California, 92037, United States
-
Neurocrine Clinical Site
Aurora, Colorado, 80045, United States
-
Neurocrine Clinical Site
Washington D.C., District of Columbia, 20007, United States
-
Neurocrine Clinical Site
Boca Raton, Florida, 33486, United States
-
Neurocrine Clinical Site
Gainesville, Florida, 32608, United States
-
Neurocrine Clinical Site
Atlanta, Georgia, 30329, United States
-
Neurocrine Clinical Site
Chicago, Illinois, 60611, United States
-
Neurocrine Clinical Site
Chicago, Illinois, 60612, United States
-
Neurocrine Clinical Site
Indianapolis, Indiana, 46202, United States
-
Neurocrine Clinical Site
Iowa City, Iowa, 52242, United States
-
Neurocrine Clinical Site
Wichita, Kansas, 67226, United States
-
Neurocrine Clinical Site
Louisville, Kentucky, 40202, United States
-
Neurocrine Clinical Site
New Orleans, Louisiana, 70121, United States
-
Neurocrine Clinical Site
Boston, Massachusetts, 02215, United States
-
Neurocrine Clinical Site
Charlestown, Massachusetts, 02129, United States
-
Neurocrine Clinical Site
Ann Arbor, Michigan, 48105, United States
-
Neurocrine Clinical Site
Omaha, Nebraska, 68105, United States
-
Neurocrine Clinical Site
Rochester, New York, 14618, United States
-
Neurocrine Clinical Site
Williamsville, New York, 14221, United States
-
Neurocrine Clinical Site
Durham, North Carolina, 27705, United States
-
Neurocrine Clinical Site
Columbus, Ohio, 43221, United States
-
Neurocrine Clinical Site
Toledo, Ohio, 43614, United States
-
Neurocrine Clinical Site
Pittsburgh, Pennsylvania, 15213, United States
-
Neurocrine Clinical Site
Charleston, South Carolina, 29425, United States
-
Neurocrine Clinical Site
Columbia, South Carolina, 29203, United States
-
Neurocrine Clinical Site
Greenville, South Carolina, 29615, United States
-
Neurocrine Clinical Site
Nashville, Tennessee, 37212, United States
-
Neurocrine Clinical Site
Houston, Texas, 77054, United States
-
Neurocrine Clinical Site
Burlington, Vermont, 05401, United States
-
Neurocrine Clinical Site
Vancouver, British Columbia, V6T 2B5, Canada
-
Neurocrine Clinical Site
Ottawa, Ontario, K1Y 4E9, Canada
-
Neurocrine Clinical Site
Toronto, Ontario, MK2 1E1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.